Clarithromycin | Levofloxacin | Metronidazole | ||||||||||
Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | |||||||
OR (95% CI) | p Value | OR (95% CI) | p Value | OR (95% CI) | p Value | OR (95% CI) | p Value | OR (95% CI) | p Value | OR (95% CI) | p Value | |
Gender | ||||||||||||
Men | 1 | 1 | 1 | |||||||||
Women | 1.40 (1.10 to 1.78) | 0.006 | 1.07 (0.82 to 1.39) | 0.59 | 1.59 (1.31 to 1.92) | 0.001 | 1.63 (1.28 to 2.09) | 0.001 | ||||
Age | ||||||||||||
<50 years | 1 | 1 | 1 | |||||||||
>50 years | 1.13 (0.89 to 1.44) | 0.305 | 1.41 (1.08 to 1.83) | 0.01 | 1.51 (1.09 to 2.09) | 0.012 | 0.91 (0.75 to 1.10) | 0.329 | ||||
Region of birth | ||||||||||||
Northern Europe* | 1 | 1 | 1 | |||||||||
Western/Central Europe† | 2.98 (1.58 to 5.61) | 0.0007 | 3.76 (1.58 to 8.97) | 0.002 | 2.71 (1.44 to 5.13) | 0.002 | 1.31 (0.90 to 1.90) | 0.157 | 1.36 (0.86 to 2.14) | 0.178 | ||
Southern Europe‡ | 3.98 (2.15 to 7.36) | 0.0001 | 5.36 (2.30 to 12.52) | 0.0001 | 2.20 (1.17 to 4.11) | 0.013 | 0.83 (0.57 to 1.19) | 0.319 | 0.95 (0.61 to 1.48) | 0.838 | ||
Outside Europe | 2.74 (1.38 to 5.43) | 0.0038 | 3.45 (1.37 to 8.68) | 0.008 | 3.22 (1.64 to 6.32) | 0.0001 | 1.75 (1.15 to 2.67) | 0.008 | 1.99 (1.20 to 3.29) | 0.007 | ||
Region of residence | ||||||||||||
Northern Europe | 1 | 1 | 1 | |||||||||
Western/Central Europe | 2.51 (1.51 to 4.18) | 0.0004 | 2.26 (1.38 to 3.69) | 0.001 | 4.41 (1.88 to 10.34) | 0.0001 | 1.77 (1.28 to 2.45) | 0.001 | ||||
Southern Europe | 3.06 (1.85 to 5.05) | 0.0001 | 1.54 (0.94 to 2.53) | 0.085 | 3.35 (1.42 to 7.88) | 0.005 | 0.99 (0.72 to 1.37) | 0.981 | ||||
Endoscopy finding | ||||||||||||
No ulcer | 1 | 1 | 1 | |||||||||
Ulcer | 0.49 (0.33 to 0.73) | 0.0001 | 0.50 (0.32 to 0.77) | 0.002 | 0.72 (0.49 to 1.05) | 0.091 | 0.65 (0.42 to 0.99) | 0.046 | 0.85 (0.65 to 1.11) | 0.233 |